Clinical trial
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
NCT00387426 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00387426 |
|---|---|
| Title | Sunitinib in Treating Patients With Idiopathic Myelofibrosis |
| Official title | A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12) and 29 more |
| Intervention type | Drug |
| Interventions | sunitinib malate |
| Enrollment | 14 |
| Start date | Sep 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Oct 13, 2006 |
| Last update posted | May 28, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: